News by community

14.10.2019 Novigenix and Radiomedix to Develop Neuroendocrine Cancer Precision Diagnostic Test

LAUSANNE, SWITZERLAND – 07:00 CET, October 14, 2019 – Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced a collaboration agreement with RadioMedix Inc., a radiopharmaceutical company, to develop a precision diagnostic test based on Novigenix’s technology. The test will measure the response in patients with neuroendocrine tumors (NET) treated with Alpha and Beta Peptide Receptor  Radionuclide Therapy (PRRT). In order to effectively monitor the response following PRRT, Novigenix will develop an immune-transcriptomic based precision diagnostic test using  its proprietary LITOseek platform to monitor the effectiveness of the treatment in NET patients.
“We are very pleased to collaborate with Novigenix on the development of a molecular signature for the response to therapy, and to detect progressive disease, earlier than any conventional modalities currently available to our NET patients,” said Dr. Ebrahim S. Delpassand, CEO of RadioMedix “Precise measurement of the therapy response against NET is extremely important for the management of NET patients.”

Press release